Literature DB >> 1986013

Systemic mastocytosis presenting as osteoporosis: a clinical and histomorphometric study.

A Chines1, R Pacifici, L V Avioli, S L Teitelbaum, P E Korenblat.   

Abstract

Ten patients with systemic mastocytosis (SM) were evaluated for their metabolic bone disease (4 men and 6 women; mean +/- SD, 59 +/- 13 yr). All patients presented with generalized osteopenia and/or atraumatic vertebral compression fractures. Three patients had long-standing urticaria pigmentosa; in these, the diagnosis of cutaneous mastocytosis had been established by skin biopsy. One of the 3 and 2 of the other 7 individuals had symptoms suggestive of SM. Although six patients had previously undergone decalcified bone marrow trephine core biopsy (DBMB), findings were consistent with SM in only 2 of them. X-Ray survey revealed generalized osteopenia in all 10 patients and vertebral compression fractures in 9. No patient had sclerotic bone lesions. Histological findings of undecalcified transiliac crest biopsy (UTBB) specimens from 9 patients (5 patients underwent both DBMB and UTBB, 4 underwent only UTBB, and 1 had only DBMB) disclosed bone marrow that contained nodules characteristic of mast cell granulomas and numerous scattered oval- and spindle-shaped mast cells. The trabecular bone contained abundant newly synthesized bone matrix and a significant increase in osteoblastic, osteoclastic, and resorptive surfaces. Dynamic histomorphometric parameters revealed a significantly increased mineral apposition rate. Our study suggests that SM may be a more frequent cause of osteoporosis than previously recognized. Generalized osteopenia with compression fractures may be the only presentation of SM. Undecalcified bone biopsy is useful in the diagnosis of SM. Accelerated bone remodeling is a characteristic histomorphometric feature of SM with diffuse osteopenia.

Entities:  

Mesh:

Year:  1991        PMID: 1986013     DOI: 10.1210/jcem-72-1-140

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

1.  Histomorphometric study of mast cells in normal bone, osteoporosis and mastocytosis using a new stain.

Authors:  M J McKenna
Journal:  Calcif Tissue Int       Date:  1994-10       Impact factor: 4.333

2.  Increased osteoblast and osteoclast indices in individuals with systemic mastocytosis.

Authors:  S Seitz; F Barvencik; T Koehne; M Priemel; P Pogoda; J Semler; H Minne; M Pfeiffer; J Zustin; K Püschel; C Eulenburg; T Schinke; M Amling
Journal:  Osteoporos Int       Date:  2013-02-23       Impact factor: 4.507

Review 3.  Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.

Authors:  Cem Akin
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

Review 4.  Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis.

Authors:  M Rossini; R Zanotti; G Orsolini; G Tripi; O Viapiana; L Idolazzi; A Zamò; P Bonadonna; V Kunnathully; S Adami; D Gatti
Journal:  Osteoporos Int       Date:  2016-02-18       Impact factor: 4.507

5.  Systemic mastocytosis with skeletal involvement: a case report and review of the literature.

Authors:  Maurizio Benucci; Catia Bettazzi; Stefania Bracci; Plinio Fabiani; Laura Monsacchi; Carlo Cappelletti; Mariangela Manfredi; Stefania Ciolli
Journal:  Clin Cases Miner Bone Metab       Date:  2009-01

6.  Case report of bone mastocytosis: total hip arthroplasty for osteoarthritis and open reduction for condylar fracture of the knee.

Authors:  H Moret; E Plihal; Y Saudan
Journal:  Clin Rheumatol       Date:  1994-12       Impact factor: 2.980

7.  Skeletal mastocytosis.

Authors:  S M Andrew; A J Freemont
Journal:  J Clin Pathol       Date:  1993-11       Impact factor: 3.411

8.  Osseous mastocytosis of the knee.

Authors:  T Harzy; A El Hajjaji
Journal:  Clin Rheumatol       Date:  2007-06-05       Impact factor: 2.980

Review 9.  The Role of Mast Cells in Bone Metabolism and Bone Disorders.

Authors:  Deniz Ragipoglu; Anne Dudeck; Melanie Haffner-Luntzer; Martin Voss; Jochen Kroner; Anita Ignatius; Verena Fischer
Journal:  Front Immunol       Date:  2020-02-07       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.